Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QD202 in Acute Ischemic Stroke Undergoing Thrombolysis
NCT07581210Phase 2Recruiting
- Sponsor
- QuietD Biotechnology
- Start
- Oct 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QD202 in ischemic stroke (3 arms), sponsored by QuietD Biotechnology. Primary endpoint: Safety and Tolerance at 90 days. Started Oct 2025; status: recruiting.
02
Drugs
QD202
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07581210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07581210.